Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA-Sponsor Interaction Could Increase Post-Pandemic With Virtual, In-Person Options

Executive Summary

Scott Gottlieb says that some meetings should remain in-person, but with virtual options proven effective, the FDA could offer more opportunities to talk to sponsors.

You may also be interested in...



US FDA/Industry Thinking PDUFA VIII Could Be A Hybrid Negotiation

Virtual meetings proved successful, and could be allowed again when the next round of user fee reauthorization talks convene.

US FDA May Rethink White Oak Campus As Agency Plots New Normal For Work

A pilot project on the future of work at the FDA could lead to reduced office space requirements and improve recruitment and retention, officials say.

US FDA May Rethink White Oak Campus As Agency Plots ‘New Normal’ For Work

A pilot project on the future of work at the FDA could lead to reduced office space requirements and improve recruitment and retention, officials say.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS145561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel